Dilaudid (Hydromorphone) Should NOT Be Used for Migraine Control
Do not use Dilaudid (hydromorphone) or any opioid for the treatment of acute episodic migraine. The most recent 2025 American College of Physicians guideline explicitly states: "Do not use opioids or butalbital for the treatment of acute episodic migraine" 1. This recommendation is further reinforced by the 2025 American Headache Society emergency department guideline, which gives hydromorphone IV a Level A recommendation to "must not be offered" for migraine treatment 2.
Why Opioids Fail in Migraine Treatment
The evidence against hydromorphone for migraine is compelling:
Inferior efficacy: A 2017 Class I randomized controlled trial demonstrated that IV prochlorperazine + diphenhydramine achieved sustained headache relief in 60% of patients versus only 31% with IV hydromorphone (number needed to treat = 4) 3. The trial was halted early by the data monitoring committee due to hydromorphone's poor performance.
Poor symptom control: Hydromorphone is substantially worse at treating migraine-associated symptoms. For nausea relief, prochlorperazine achieved 69.4% complete resolution versus 30.6% with hydromorphone (absolute risk reduction 38.8%) 4. Similar deficits were seen for photophobia and phonophobia.
Medication overuse risk: Opioids carry significant risk of medication overuse headache, addiction, abuse, and respiratory depression 1, 5.
What You Should Use Instead
Follow this algorithmic approach based on 2025 ACP guidelines 1:
First-Line Treatment
- Start with NSAIDs or acetaminophen at adequate doses
- If inadequate response: Add a triptan to the NSAID (or to acetaminophen if NSAIDs contraindicated)
- This combination therapy should be initiated as soon as possible after migraine onset
Second-Line Options (if combination therapy fails)
- CGRP antagonists (gepants): rimegepant, ubrogepant, zavegepant
- Ergot alkaloid: dihydroergotamine
- Ditan: lasmiditan (only after all other options have failed)
Emergency Department Setting
If parenteral therapy is required 2:
- Must offer (Level A): Prochlorperazine IV or greater occipital nerve blocks
- Should offer (Level B): Dexketoprofen IV, ketorolac IV, metoclopramide IV, sumatriptan SC, supraorbital nerve blocks
- Must NOT offer (Level A): Hydromorphone IV
Critical Pitfalls to Avoid
Never use opioids as first-line therapy: The 2016 AHS guideline already recommended avoiding morphine and hydromorphone as first-line therapy (Level C), and this has been strengthened to an absolute contraindication in 2025 guidelines 6, 2.
Ensure adequate dosing before escalating: Many patients receive subtherapeutic doses of NSAIDs or acetaminophen. Optimize these before adding additional agents 1.
Watch for medication overuse: The threshold is ≥10 days per month for triptans and ≥15 days per month for NSAIDs 1.
The FDA labeling for Dilaudid indicates it is approved for "management of pain severe enough to require an opioid analgesic" but makes no mention of migraine as an indication 5. Given the robust evidence demonstrating both inefficacy and harm, hydromorphone has no role in modern migraine management.